Katherine Tuttle University of Washington School of Medicine, Division of NephrologyUnited States

KatherineTuttle
Katherine R. Tuttle, MD, FASN, FACP, FNKF, is Executive Director for Research at Providence Inland Northwest Health and Professor of Medicine at the University of Washington. Dr. Tuttle’s collective body of work has shaped the “pillars of therapy“ approach to chronic kidney disease and cardiovascular disease in a fundamental manner across the spectrum of scientific discovery, clinical trials, and population level implementation. She is chair of the Diabetic Kidney Disease Collaborative for the American Society of Nephrology and a member of the Cardio-Kidney-Metabolic working group for the American Heart Association. She has chaired numerous national and international initiatives including the inaugural National Kidney Foundation-KDOQI Guideline for Diabetes and Chronic Kidney Disease, the American Diabetes Association Diabetes and Chronic Kidney Disease Consensus Conference, International Society of Nephrology - World Congress of Nephrology, and the Kidney Health Initiative. Dr. Tuttle has received many honors and awards including the John P. Peters Lifetime Achievement Award from the American Society of Nephrology, the Medal of Excellence from the American Association of Kidney Patients, the Garabed Eknoyan Award from the National Kidney Foundation, the YWCA Woman of Achievement Award in Science, and two Outstanding Clinical Faculty Awards at the University of Washington.
Upload Picture
https://storage.unitedwebnetwork.com/files/1099/6b7c2f0f557b979fe64bdf671fc5433d.jpg
First Name
Katherine
Last Name
Tuttle
Institution
Country.
United States

Friday, February 7, 2025

Time Session
2:15 p.m.
3:45 p.m.
ChairParminder Kaur Judge University of Oxford, UKUnited Kingdom
ChairVineet Behera Consultant Nephrologist & Professor Medicine, INHS Kalyani, VisakhapatnamIndia
  • Cardiovascular-Kidney-Metabolic Syndrome: What Does it Mean?
    SpeakerKatherine Tuttle University of Washington School of Medicine, Division of NephrologyUnited States
  • GLP-1 RA in Kidney Disease: Beyond T2DM Control
    SpeakerBeatriz Fernandez-Fernandez Hospital Universitario Fundación Jimenez Díaz Spain
  • New Frontiers in CKD Therapy: Endothelin Receptor Antagonists
    SpeakerMaria Jose Soler Hospital del Vall d´HebronSpain
  • Myocardial Infarction in Kidney Disease - What Should a Nephrologist Know?
    SpeakerSydney Tang Hong Kong, China
  • Q&A
Amaltas Hall B101-B
ChairAndrea Viecelli University of QueenslandAustralia
ChairVivek Kumar Postgraduate Institute of Medical Education and Research, Chandigarh, IndiaIndia
  • Combination Effect of Finerenone and Empagliflozin in Participants With Chronic Kidney Disease and Type 2 Diabetes Using a UACR Endpoint Study (CONFIDENCE)
    Oral Abstract PresenterRajiv Agarwal United States
  • Results From the REGENCY Trial Assessing Efficacy and Safety of Obinutuzumab in Active Lupus Nephritis
    Oral Abstract PresenterBrad Rovin The Ohio State UniversityUnited States
  • Clinical and Safety Outcomes of Semaglutide by CKD Severity in the FLOW trial
    Oral Abstract PresenterKatherine Tuttle University of Washington School of Medicine, Division of NephrologyUnited States
Brahmkamal Hall - Plenary Hall

Saturday, February 8, 2025

Time Session
4:15 p.m.
5:15 p.m.
ChairDenis Georges Teuwafeu University of Buea, Faculty of Health Sciences Cameroon
ChairRobert Kalyesubula Makerere, UniversityUganda
ChairRoberto Pecoits Filho Arbor Research Collaborative for HealthUnited States
  • A Nephrologist Perspective on the Cardio-Kidney-Metabolic Syndrome
    SpeakerJanani Rangaswami Professor of Medicine, George Washington University School of MedicineUnited States
  • Optimizing CKD Management in the Context of Diabetes and Obesity
    SpeakerRoberto Pecoits Filho Arbor Research Collaborative for HealthUnited States
  • Combining Therapies for Cardio-Kidney-Metabolic Conditions: An Integrative Approach
    SpeakerKatherine Tuttle University of Washington School of Medicine, Division of NephrologyUnited States
  • Q&A
Champa Hall 304

Thursday, February 6, 2025

Time Session
11:30 a.m.
1:30 p.m.
ChairKenar Jhaveri Northwell HealthUnited States
ChairMitchell Rosner Univeristy of Virginia HealthUnited States
  • Clinical Trials Overview: Focus on GLP1a, MRA, and SGLT2
    SpeakerMaarten Taal University of NottinghamUnited Kingdom
  • SGLT2i Versus GLP1a And/or MRA Versus SGLT2i, And/or Starting All Together: What Should the Clinician Do? My Approach
    SpeakerKatherine Tuttle University of Washington School of Medicine, Division of NephrologyUnited States
  • SGLT2i Versus GLP1a And/or MRA Versus SGLT2i, And/or Starting All Together: What Should the Clinician Do? My Approach
    SpeakerMadhukar Misra University of Missouri Columbia, USAUnited States
  • Q and A
Neelkamal Hall 305